Gradient Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gradient Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-113	Closed	-$27.5K	–	331
2024 Q2	$27.5K	Buy	113 +1	+0.9%	+$158	﹤0.01%	587
2024 Q1	$16.7K	Sell	112 -2	-2%	-$334	﹤0.01%	577
2023 Q4	$21.8K	Hold	114	–	–	﹤0.01%	691
2023 Q3	$20.2K	Sell	114 -2	-2%	-$382	﹤0.01%	679
2023 Q2	$22K	Buy	116 +6	+5%	+$1.19K	﹤0.01%	670
2023 Q1	$22K	Sell	110 -1	-0.9%	-$210	﹤0.01%	663
2022 Q4	$26.4K	Buy	111 +1	+0.9%	+$213	﹤0.01%	634
2022 Q3	$22K	Hold	110	–	–	﹤0.01%	646
2022 Q2	$16K	Hold	110	–	–	﹤0.01%	680
2022 Q1	$18K	Hold	110	–	–	﹤0.01%	663
2021 Q4	$19K	Hold	110	–	–	﹤0.01%	669
2021 Q3	$21K	Hold	110	–	–	﹤0.01%	629
2021 Q2	$19K	Hold	110	–	–	﹤0.01%	644
2021 Q1	$16K	Hold	110	–	–	﹤0.01%	657
2020 Q4	$16K	Hold	110	–	–	﹤0.01%	607
2020 Q3	$16K	Hold	110	–	–	﹤0.01%	611
2020 Q2	$16K	Hold	110	–	–	﹤0.01%	562
2020 Q1	$12K	Hold	110	–	–	﹤0.01%	606
2019 Q4	$13K	Hold	110	–	–	﹤0.01%	634
2019 Q3	$9K	Hold	110	–	–	﹤0.01%	678
2019 Q2	$8K	Buy	+110	New	+$8.44K	﹤0.01%	695

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gradient Investments's ALNY Position: Q3 2024 in Review

Gradient Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 113 shares — an estimated $27.5K sold.

Gradient Investments first reported a position in ALNY in Q2 2019 and held it in 21 quarters. The position peaked at $27.5K in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Gradient Investments reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Gradient Investments sold 113 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $27.5K.
Gradient Investments first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 21 quarters.
Gradient Investments's Alnylam Pharmaceuticals position peaked at $27.5K in Q2 2024.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.